Lomas-Lee M, Bocanegra-García V, Ordaz-Pichardo C, González J, Rivera G

Idioma: Ingles.
Referencias bibliográficas: 29
Paginas: 21-25
Archivo PDF: 78.25 Kb.

RESUMEN

La terapia de combinación para el tratamiento de la dislipidemia ha sido habitual en pacientes con enfermedad coronaria. Sin embargo, también puede aumentar el riesgo de efectos adversos graves, como las mialgias y la rabdomiólisis. En este estudio analizamos las características de 527 pacientes mexicanos con hipercolesterolemia para evaluar los efectos de las estatinas y fibratos en la actividad plasmática de creatina fosfoquinasa (CPK) después de tres meses de tratamiento. Atorvastatina, pravastatina y rosuvastatina mostraron una diferencia estadísticamente significativa en niveles de CPK (p ‹ 0.05). Cuatro pacientes (0.75%) presentaron de manera moderada y transitoria niveles de CPK de hasta 3 veces el límite superior, los pacientes refirieron mialgias. Aunque los tratamientos con estatinas y fibratos son seguros, vigilar los niveles en plasma de CPK durante el tratamiento sigue siendo recomendable.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Habib G, Paillard F, Charpentier G, Angellieer JF, Roux T, Portal JJ, et al. Multicenter, open-label, randomized study comparing the efficacy of atorvastatin versus usual care in reducing refractory hypercholesterolemia in high-risk patients to target levels. Curr Therap Res. 2000; 61: 175-85.

2. Malhotra S, Grover A, Munjai G. Status of statins, utilization and unanswered questions. Pharmacotherapy. 2001; 3: 15-21.

3. Pedersen TR, Olsson AG, Faergeman O, Kjekshus J, Wedel H, Berg K, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian simvastatin survival study. Circulation. 1998; 97: 1453-60.

4. Wang TJ, Stafford RS, Ausiello JC, Chaisson CE. Randomized clinical trials and recent patterns in the use of statins. Am Heart J. 2001; 141: 957-63.

5. Weffald LA, Flach LA. Myopathy associated with atorvastatin-ezetimibe combination therapy. Pharmacotherapy. 2007; 27: 309-11.

6. Carvalho AA, Lima UW, Valiente RA. Statin and fibrate associated miopathy: study of eight patients. Arq Neuro-Psiquiatric. 2004; 62(2A): 257-61.

7. Wortmann RL. Myositis and myopathies. Lipid lowering agents and myopathy. Curr Opin Rheumat. 2002; 14: 643-647.

8. Baer AN, Wortmann RL. Myotoxicity associated with lipid-lowering drugs. Curr Opin Rheumatol. 2007; 19: 67-73.

9. Meas T, Cimadevilla C, Timsit J, Mouly S, Guillausseau PJ. Elevation of CPK induced by ezetimibe in monotheraphy: report on two cases. Diabetes Metab. 2006; 32: 364-6.

10. Langford NL, Kendall ML. Rhabdomyolysis with HMG CoA reductase inhibitors: a class effect? J Clinical Pharm Therap. 2001; 26: 391-5.

11. Phillips PS, Haas RH, Bannykh S, Hathaway S, Gray NL, Kimura BJ, et al. Statin-associated myopathy with normal CPK levels. Ann Inter Med. 2002; 137: 581-5.

12. Troseid M, Henriksen OA, Lindal S. Statin-associated myopathy with normal creatine kinase levels. Case report from a Norwegian family. Act Pathologic Microbio Immunol Scand. 2005; 113: 635-7.

13. Omar MA, Wilson JP. FDA Adverse event reports on statin-associated rhabdomyolysis. Ann Pharmacother. 2002; 36: 288-95.

14. Wooltorton E. Bayer pulls cerivastatin (Baycol) from market. CMAJ. 2001; 165: 632.

15. ICD-9-CM Volumes 1 and 2 - Diagnosis Codes, International Classification of Diseases, Ninth Revision, Clinical Modification.

16. Henderson AR, McQueen MJ, Patten RL, Krishnan S, Wood DE, Webb S. Testing for creatine kinase and creatine kinase-2 in Ontario: reference ranges and assay types. Clin Chem. 1992; 38: 1365-70.

17. McKenney JM, Davidson MH, Saponaro J, Thompson PD, Bays HE. Use of a treatment algorithm to achieve NCEP ATP III goals with atorvastatin. J Cardiovasc Pharmacol. 2005; 46: 594-9.

18. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, Grenade LL, et al. Incidence of hospitalized rhabdomyolysis in patients treated with lipid lowering. JAMA. 2004; 292: 2585-90.

19. Scott LJ, Curran MP, Figgitt DP. Rosuvastatin: a review of its use in the management of dyslipidemia. Am J Cardiovasc Drugs. 2004; 4: 117-38.

20. Skrabal MZ, Stading JA, Cannella CA, Monaghan MS. Two Cases of rhabdomyolysis associated with high-dose simvastatin. Am J Health Syst Pharm. 2003; 60: 578-81

21. Federman DG, Hussain F, Walters AB. Fatal rhabdomyolysis caused by lipid-lowering therapy. South Med J. 2001; 94: 1023-6.

22. Lau TK, Leachman R, Lufschanowski R. Severe rhabdomyolysis associated with the cerivastatin-gemfibrozil combination therapy. Tex Heart Inst J. 2001; 28: 142-5.

23. Murdock DK, Murdock AK, Murdock RW, Olson KJ, Frane AM, Kersten ME, et al. Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders. Am Heart J. 1999; 138(1 pt 1): 151-5.

24. Pasternak RC, Smith SC, Bairey-Merz CN, Grundy SM, Cleeman JI, Lenfant C. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. J Am Coll Cardiol. 2002; 40: 567-72.

25. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, et al. STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003; 92: 152-60.

26. Ong HT. Protecting the heart: a practical review of the statin studies. Med Gen Med. 2002; 4: 1.

27. No authors listed. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994; 344: 1383-9.

28. McKenney JM, Jones PH, Bays HE, Knopp RH, Kashyap ML, Ruoff GE, et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study). Atherosclerosis. 2007; 192: 432-7.

29. Leiter LA, Rosenson RS, Stein E, Reckless JP, Schulte KL, Schleman M, et al; POLARIS study investigators. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis. 2007; 194(2): e154-64.